Human Pheromone Sciences Inc. reported unaudited earnings results for the fourth quarter and the year ended December 31, 2011. For the quarter, net revenue was $146,000, representing a 35% decrease from revenues of $225,000 in the prior year period, and resulted in net income of $12,000 or $0.00 per basic and diluted share as compared with net income of $118,000 or $0.03 per basic and diluted share for the same period last year. Income from operations was $7,000 against $118,000 for the same period last year. Income before provision for income taxes was $12,000 against $118,000 for the same period last year. For the year ending December 31, 2011, net revenues of $569,000, were 29% less than revenues of $806,000 generated in the year ended December 31, 2010. The net loss in the current year of $44,000 $0.01 per basic and diluted share was $53,000, or 55%, reduction from the $97,000 loss or $0.02 per basic and diluted share recorded for the year ended December 31, 2010. Revenues in 2011 were either flat or less than 2011 in each quarter and revenues by customer were all less than in 2010. This decrease was attributable to the depressed global economic conditions and the lack of new product or product line expansions during the year, and an Asian customer converting to a non-exclusive license. Loss from operations was $47,000 against $95,000 for the same period last year. Loss before provision for income taxes was $43,000 against $95,000 for the same period last year. The company filed a form 15 with the SEC. The company filed a form 15 with the SEC in order to effect a termination of registration of its common stock under the Securities Exchange Act of 1934. Upon this voluntary filing the company is no longer required to file periodic and current reports with the SEC, including forms 10-K, 10-Q and 8-K. The company expects that its common stock will continue to be traded in the Pink Sheets under the symbol, EROX.